The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient.
A retrospective analysis of prospectively collected data was performed to compare the frequency of upper gastrointestinal bleeding (GIB) in seriously burned patients treated with either cimetidine and antacids or enteral nutrition for ulcer prophylaxis. Five hundred and twenty-six seriously burned patients admitted to the burn intensive care unit of the BG Trauma Centre Ludwigshafen during a 4-year period were included into the study. All patients admitted to the burn unit from 1989 to 1991 received i.v. cimetidine (400 mg q4) for ulcer prophylaxis. If the intragastric pH dropped below 3.5, gastric pH was titrated with antacids up to > or = 4 via nasogastric tube. During the second 2-year period (1992-1993) early enteral nutrition alone was regarded to be ulcer protective and no further interventions for ulcer prophylaxis were routinely performed. Signs of overt upper GIB were monitored and documented through the entire study period. The overall occurrence rate of upper GIB in the cimetidine/antacids (C/A) group (n = 253) was 8.3 per cent with six cases of serious bleeding in five patients (1.98 per cent). In the enteral nutrition (EN) group (n = 273) the overall incidence of GIB was 3.3 per cent with two cases of serious bleeding (0.73 per cent). There were no deaths directly related to ulcer haemorrhage. The difference in the overall frequency of overt GIB between the groups studied was statistically significant (< 0.05). In our experience, early enteral nutrition is effective in the prevention of stress haemorrhage in the upper gastrointestinal tract. Additional medicinal prophylaxis is not required in burn patients.
Raff
T
T
Department of Plastic and Hand Surgery, BG-Unfallklinik Ludwigshafen, Germany.
Germann
G
G
Hartmann
B
B
D000284:Administration, Oral; D000328:Adult; D000863:Antacids / Q000008:administration & dosage / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002056:Burns / Q000150:complications* / Q000175:diagnosis / Q000401:mortality; D002927:Cimetidine / Q000008:administration & dosage / Q000627:therapeutic use; D016145:Endoscopy, Digestive System; D004750:Enteral Nutrition / Q000379:methods; D005260:Female; D006801:Humans; D007441:Intubation, Gastrointestinal; D008297:Male; D010437:Peptic Ulcer / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D010438:Peptic Ulcer Hemorrhage / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D011446:Prospective Studies; D012121:Respiration, Artificial; D012720:Severity of Illness Index; D013312:Stress, Physiological / Q000150:complications*; D015996:Survival Rate
D000863:Antacids; D000897:Anti-Ulcer Agents; D002927:Cimetidine